Page 41 - Livre électronique du congrès national de pneumologie 2024

patients in both groups (83% in Group 1 vs. 70%
P26 in Group 2). Tuberculosis sequelae were the
predominant etiology in Group 1, while post-
ASSESSING THE IMPACT OF infectious sequelae were the main etiology in
INHALED CORTICOSTEROIDS ON Group 2. Other etiologies included connective
EXACERBATION FREQUENCY IN tissue disorders (13.3% vs. 0%), ciliary dyskinesia
(10% vs. 3.3%), and Kartagener syndrome, which
BRONCHIECTASIS: A was only found in Group 2. Immunodeficiency
COMPARATIVE ANALYSIS. and cystic fibrosis each accounted for 3.3% in
both groups. Pseudomonas aeruginosa
O. BEN LAKHAL1, C.JNEYEH, A.FRADI, M.KLILA, J.ELGHOUL colonization was found in 16.7% of Group 1 vs.

HOPITAL HABIB BOURGUIBA MEDENINE1 13.3% of Group 2 (p=0.1). In Group 1, the average
number o exacerbation requiring
Introduction: hospitalization in pulmonology per year was

Bronchiectasis (DDB) is a chronic pulmonary 1.27 vs. 1.07 in Group 2 (p=0,08). In Group 1, the
condition characterized by abnormal bronchial percentage of patients requiring non-invasive
dilation, often associated with recurrent ventilation (NIV) and admission to an intensive
inflammation and infection of the airways. care unit (ICU) were 13.3% and 10%, respectively
Inhaled corticosteroids are commonly used to (p = 0.6).
manage inflammation in various chronic lung Conclusion :
diseases, but their effectiveness in reducing
exacerbations in patients with bronchiectasis Our finding suggest that inhaled
remains a topic of ongoing debate. corticosteroids does not impact the number of
exacerbations in patients with bronchiectasis .
Objective:
The use of inhaled corticosteroids should be
This study investigates the impact of inhaled individualized and integrated into a
corticosteroid on th frequency o comprehensive disease management strategy.
exacerbations in patients with bronchiectasis. Additional research is needed to clarify optimal

Methods: use conditions and to identify which patients
may derive the most benefit from this treatment.
Analytical study involving 60 patients who
were hospitalized in the pulmonology
department of Habib Bourguiba hospital ,
Medenine between 2014 and 2024. Two
groups were compared: Group 1 (G1) consisting
o 30 patient receiving inhaled
corticosteroids, and Group 2 (G2) consisting of
30 patient not receiving inhaled
corticosteroids.

Result:

The two groups were similar in terms of age,
sex, Neffa and tobacco consumption. We
found a higher prevalence of asthma in Group 1
(56% vs. 10%) and more patients with chronic
respiratory failure (43.3% vs. 16.7%). Bilateral
bronchiectasis was observed in the majority of

Page 36